The ECFS-CTN cannot guarantee that the information provided here is comprehensive. Please go to the ClinicalTrials.gov link for detailed and up-to-date information on study background, eligibility criteria, study design, outcome measures, study status, participating sites, sponsor contact information and timelines.

You can also contact the CTN coordinating centre for additional information: ECFS-CTN@uzleuven.be

Study TitleA Phase 2a, Randomized, Placebo-Controlled, Double-Blind
Multiple Ascending Dose Study in Patients with Cystic Fibrosis 
Carrying the 3849 +10 Kb C->T Mutation to Evaluate the Safety, 
Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPL84
Study DrugSPL84
Type of Study DrugGenetic therapy
Study Phase2a
Study SponsorSpliSense

Link in registry(ies)

https://clinicaltrials.gov/study/NCT06429176 
Participating ECFS-CTN sitesPlease contact ecfs-ctn@uzleuven.be for most recent sitelist
AgeAdult patients